

# 2016 Reportable Disease Changes

---

# 2016 Changes to Michigan's Reportable Diseases

---

SUMMARY DISTRIBUTED ON JANUARY 20



# 2016 Reportable Diseases – by Pathogen or by Condition

Available at:

[www.michigan.gov/cdinfo](http://www.michigan.gov/cdinfo)

## 2016 REPORTABLE DISEASES IN MICHIGAN – BY CONDITION

### A Guide for Physicians, Health Care Providers and Laboratories

Report the following conditions to the Michigan Disease Surveillance System (MDSS) or local health department (see reverse) within 24 hours (unless otherwise noted) if the agent is identified by clinical or laboratory diagnosis.

Report the unusual occurrence, outbreak or epidemic of any disease or condition, including health care-associated infections.

Anaplasmosis (Anaplasma phagocytophilum)	Measles (Measles/Rubella virus)
Anthrax (Bacillus anthracis) (4)	Melioidosis (Burkholderia pseudomallei) (4)
Arboviral encephalitis, neuro- and non-neuroinvasive: Chikungunya, Eastern Equine, Jamestown Canyon, La Crosse, Powassan, St. Louis, Western Equine, West Nile	Meningitis: bacterial, viral, fungal, and parasitic
Babesiosis (Babesia microti)	Meningococcal Disease (Neisseria meningitidis, sterile sites) (5)
Blastomycosis (Blastomyces dermatitidis)	Middle East Respiratory Syndrome (MERS-CoV) (5)
Bruceellosis (Brucella species) (4)	Mumps (Mumps virus)
Campylobacteriosis (Campylobacter species)	Ornithox virus (including Smallpox, Morleypox) (4)
Chancroid (Haemophilus ducreyi)	Pertussis (Bordetella pertussis)
Chickenpox / Varicella (Varicella virus) (6)	Plague (Yersinia pestis) (4)
Chlamydial infections (including trachoma, genital infections, LGV) (Chlamydia trachomatis) (3)(6)	Polio (Poliovirus)
Cholera (Vibrio cholera) (4)	Prión disease (including CJD)
Coccidioidomycosis (Coccidioides immitis)	Psittacosis (Chlamydia psittaci)
Cryptosporidiosis (Cryptosporidium species)	Q Fever (Coxiella burnetii) (4)
Cyclosporiasis (Cyclospora species)	Rabies (Rabies virus)
Dengue Fever (Dengue virus)	rheumatic fever (1)
Diphtheria (Corynebacterium diphtheriae) (5)	Rubella (Rubella virus) (6)
Ehrlichiosis (Ehrlichia species)	Salmonellosis (Salmonella species) (5)
Encephalitis, viral or unspecified	Severe Acute Respiratory Syndrome (SARS) (5)
Escherichia coli, O157:H7 and all other Shiga toxin producing serotypes (5)	Shigellosis (Shigella species) (5)
Giardiasis (Giardia species)	Spotted Fever and Typhus Group (Rickettsia species)
Glanders (Burkholderia mallei) (4)	Staphylococcus aureus (MRSA), outbreaks only
Gonorrhea (Neisseria gonorrhoeae) (3)(6)	Staphylococcus aureus, vancomycin intermediate/ resistant (VISA) (5)/VRSA (4)
Guillain-Barre Syndrome (1)	Streptococcus pneumoniae, sterile sites
Haemophilus influenzae, sterile sites only; submit isolates for serotyping for patients < 15 years of age (5)	Streptococcus pyogenes, group A, sterile sites, including Streptococcal Toxic Shock Syndrome (STSS)
Hantavirus	Syphilis (Treponema pallidum) (6)
Hemolytic Uremic Syndrome (HUS)	Tetanus (Clostridium tetani)
Hepatitis, viral:	Toxic Shock Syndrome (non-streptococcal) (1)
Hepatitis A virus (Anti-HAV IgM)	Trichinellosis (Trichinella spiralis)
Hepatitis B virus (HBsAg, HBeAg, anti-HBc IgM, HBV NAAT, HBV genotype, report all HBsAg and anti-HBc (positive, negative, indefinite) for children ≤ 5 years of age by 2017) (6)	Tuberculosis (Mycobacterium tuberculosis complex); report all preliminary and final TB NAAT, TB genetic probe, chromatographic or other rapid test results (5)
Hepatitis C virus (Anti-HCV, HCV NAAT, HCV genotype) (6)	Tularemia (Francisella tularensis) (4)
Hepatitis D virus (HDsAg, anti-HDV IgM)	Typhoid Fever (Salmonella typhi) (5)
Hepatitis E virus (Anti-HEV IgM)	Vibriosis (Non-cholera species) (5)
Histoplasmosis (Histoplasma capsulatum)	Yellow Fever (Yellow Fever virus)
HIV tests including reactive immunoassays (e.g., WB, EIA, IA), detection tests (e.g., VL, NAAT, p24 genotype), CD4 counts/ percent, and all tests related to perinatal exposures) (2)(5)(6)	Yersiniosis (Yersinia enterocolitica)
Influenza virus (weekly aggregate counts)	
Pediatric mortality, report individual cases	
Novel influenza virus or, report individual cases (5)(6)	
Kawasaki Disease (1)	
Legionellosis (Legionella species) (5)	
Leprosy or Hansen's Disease (Mycobacterium leprae)	
Leptospirosis (Leptospira species)	
Listeriosis (Listeria monocytogenes) (5)(6)	
Lyme Disease (Borrelia burgdorferi)	
Malaria (Plasmodium species)	

### LEGEND

- (1) Reporting within 3 days is required.
  - (2) Reporting within 7 days is required.
  - (3) Sexually transmitted infections for which expedited partner therapy is authorized. See [www.michigan.gov/hivstd](http://www.michigan.gov/hivstd) for details.
  - (4) A laboratory shall immediately submit suspect or confirmed isolates, subcultures, or specimens from the patient being tested to the MDHHS Lansing laboratory.
  - (5) Isolate requested. If not available from non-culture based testing, the positive broth and/or stool in transport medium must be submitted to the MDHHS Lansing laboratory.
  - (6) Report pregnancy status, if available.
- Blue Bold Text** = Category A bioterrorism agent, notify the MDHHS Laboratory immediately: (517) 335-8063

This reporting is expressly allowed under HIPAA and required by Michigan Public Act 368 of 1976, 333 5111  
MDHHS maintains, reviews, and revises this list at least annually. For the most recent version please refer to [www.michigan.gov/cdinfo](http://www.michigan.gov/cdinfo).  
Michigan Department of Health and Human Services • Bureau of Laboratories • Bureau of Disease Control, Prevention, and Epidemiology REV. 01/16

## 2016 REPORTABLE DISEASES IN MICHIGAN – BY PATHOGEN

### A Guide for Physicians, Health Care Providers and Laboratories

Report the following conditions to the Michigan Disease Surveillance System (MDSS) or local health department (see reverse) within 24 hours (unless otherwise noted) if the agent is identified by clinical or laboratory diagnosis.

Report the unusual occurrence, outbreak or epidemic of any disease or condition, including health care-associated infections.

Anaplasma phagocytophilum (Anaplasmosis)	Leptospira species (Leptospirosis)
Arboviral encephalitis, neuro- and non-neuroinvasive: Chikungunya, Eastern Equine, Jamestown Canyon, La Crosse, Powassan, St. Louis, Western Equine, West Nile	Listeria monocytogenes (Listeriosis) (5)(6)
Bacillus anthracis (Anthrax) (4)	Measles virus (Measles/Rubella)
Blastomycosis (Blastomyces dermatitidis)	Meningitis: bacterial, viral, fungal, and parasitic
Bordetella pertussis (Pertussis)	Mumps virus
Borrelia burgdorferi (Lyme Disease)	Mycobacterium leprae (Leprosy or Hansen's Disease)
Brucella species (Brucellosis) (4)	Mycobacterium tuberculosis complex (Tuberculosis); report all preliminary and final TB NAAT, TB genetic probe, chromatographic or other rapid test results (5)
Burkholderia mallei (Glanders) (4)	Neisseria gonorrhoeae (Gonorrhea) (3)(6)
Burkholderia pseudomallei (Melioidosis) (4)	Neisseria meningitidis, sterile sites (Meningococcal Disease) (5)
Campylobacter species (Campylobacteriosis)	Orthopox viruses (including Smallpox, Morleypox) (4)
Chlamydia trachomatis (Trachoma, Genital infections, LGV) (3)(6)	Plasmodium species (Malaria)
Chlamydia psittaci (Psittacosis)	Poliovirus
Clostridium botulinum (Botulism) (4)	Prión disease (including CJD)
Clostridium tetani (Tetanus)	Rabies virus
Coccidioides immitis (Coccidioidomycosis)	Rheumatic fever (1)
Corynebacterium diphtheriae (Diphtheria) (5)	Rickettsia species (Spotted Fever and Typhus Group)
Coxiella burnetii (Q Fever)	Rubella virus (6)
Cryptosporidium species (Cryptosporidiosis)	Salmonella species (Salmonellosis) (5)
Cyclospora species (Cyclosporiasis)	Salmonella typhi (Typhoid Fever) (5)
Dengue virus (Dengue Fever)	Shigella species (Shigellosis) (5)
Ehrlichiosis (Ehrlichia species)	Staphylococcus aureus (MRSA), outbreaks only
Encephalitis, viral or unspecified	Staphylococcus aureus, vancomycin intermediate/ resistant (VISA) (5)/VRSA (4)
Escherichia coli, O157:H7 and all other Shiga toxin producing serotypes (including HUS) (5)(6)	Streptococcus pneumoniae, sterile sites
Francisella tularensis (Tularemia) (4)	Streptococcus pyogenes, group A, sterile sites, including Streptococcal Toxic Shock Syndrome (STSS)
Giardiasis (Giardia species)	Tetanus (Clostridium tetani)
Guillain-Barre Syndrome (1)	Toxic Shock Syndrome (non-streptococcal) (1)
Haemophilus ducreyi (Chancroid)	Trichinellosis (Trichinella spiralis)
Haemophilus influenzae, sterile sites only; submit isolates for serotyping for patients < 15 years of age (5)	Tuberculosis (Mycobacterium tuberculosis complex); report all preliminary and final TB NAAT, TB genetic probe, chromatographic or other rapid test results (5)
Hantavirus	Tularemia (Francisella tularensis) (4)
Hepatitis, viral:	Typhoid Fever (Salmonella typhi) (5)
Hepatitis A virus (Anti-HAV IgM)	Vibriosis (Non-cholera species) (5)
Hepatitis B virus (HBsAg, HBeAg, anti-HBc IgM, HBV NAAT, HBV genotype, report all HBsAg and anti-HBc (positive, negative, indefinite) for children ≤ 5 years of age by 2017) (6)	Yellow Fever (Yellow Fever virus)
Hepatitis C virus (Anti-HCV, HCV RNA nucleic acid tests (PCR, HCV genotype) (6)	Yersiniosis (Yersinia enterocolitica)
Hepatitis D virus (HDsAg, anti-HDV IgM)	
Hepatitis E virus (Anti-HEV IgM)	
Histoplasma capsulatum (Histoplasmosis)	
HIV tests including reactive immunoassays (e.g., WB, EIA, IA), detection tests (e.g., VL, NAAT, p24 genotype), CD4 counts/ percent, and all tests related to perinatal exposures) (2)(5)(6)	
Influenza virus (weekly aggregate counts)	
Pediatric mortality, report individual cases	
Novel influenza virus or, report individual cases (5)(6)	
Kawasaki Disease (1)	
Legionella species (Legionellosis) (5)	

### LEGEND

- (1) Reporting within 3 days is required.
  - (2) Reporting within 7 days is required.
  - (3) Sexually transmitted infections for which expedited partner therapy is authorized. See [www.michigan.gov/hivstd](http://www.michigan.gov/hivstd) for details.
  - (4) A laboratory shall immediately submit suspect or confirmed isolates, subcultures, or specimens from the patient being tested to the MDHHS Lansing laboratory.
  - (5) Isolate requested. If not available from non-culture based testing, the positive broth and/or stool in transport medium must be submitted to the MDHHS Lansing laboratory.
  - (6) Report pregnancy status, if available.
- Blue Bold Text** = Category A bioterrorism agent, notify the MDHHS Laboratory immediately: (517) 335-8063

This reporting is expressly allowed under HIPAA and required by Michigan Public Act 368 of 1976, 333 5111  
MDHHS maintains, reviews, and revises this list at least annually. For the most recent version please refer to [www.michigan.gov/cdinfo](http://www.michigan.gov/cdinfo).  
Michigan Department of Health and Human Services • Bureau of Laboratories • Bureau of Disease Control, Prevention, and Epidemiology REV. 01/16

# 2016 Michigan Changes

---

- Removed Amebiasis (not currently nationally notifiable)
- Arboviral condition “California Group” specified as Jamestown Canyon & La Crosse viruses
- Separated Coronavirus infection into SARS and MERS (on ‘By Condition’ list)
- Moved HUS to E. Coli section (on ‘By Pathogen’ list)
- Hepatitis B - added HBsAg and anti-HBs (positive, negative, indeterminate) for children 5 years of age and younger

# 2016 Michigan Changes

---

- Updated HIV lab information
- Changed “Toxic Shock Syndrome (non-streptococcal)” to “Staphylococcus aureus Toxic Shock Syndrome” (on ‘By Pathogen’ list)
- Changed “Viral Hemorrhagic Fever” to “Hemorrhagic Fever Viruses”
- Added pregnancy status reporting requirement for:
  - Chlamydia, STEC, Hepatitis B, Hepatitis C, HIV, Novel Influenza, Listeriosis, Gonorrhea, Rubella, Syphilis, Chickenpox

# 2016 Michigan Changes

---

- Clarified Mycobacterium tuberculosis lab information: “report all **preliminary and final** TB NAAT, TB genetic probe, chromatographic or other rapid test results”
  
- Clarified language for the lab submission: “A laboratory shall **immediately submit suspect or confirmed** isolates, subcultures, or specimens from the patient being tested to the MDHHS Lansing Laboratory”
  - Anthrax, Brucellosis, Glanders, Melioidosis, Botulism, Tularemia, Hemorrhagic Fever Viruses, Orthopox viruses (Smallpox, Monkeypox), VRSA, Cholera, and Plague

# 2016 Michigan Changes

---

- Clarified language for lab submission: “Isolate requested. If not available from non-culture based testing, the positive broth and/or stool in transport medium must be submitted to the MDHHS Laboratory”
- Coronavirus (SARS, MERS-CoV), Diphtheria, E. coli O157:H7, Haemophilus influenza for patients <15 years, HIV, Legionellosis, Listeriosis, TB, Meningococcal Diseases, Novel Influenza, Salmonellosis, Typhoid Fever, Shigellosis, VISA, Cholera, Vibriosis (non-Cholera)

# 2016 Health Care Professional's Guide to Disease Reporting in Michigan (Brick Book)

---





# 2016 Brick Book Changes

---

- Changes to reportable disease list reflected in Brick Book lists and language
- Re-organized sections (though individual sections remain unchanged)
  - How to Report – MDSS (p5)
  - Expedited Partner Services (p9-10)
  - Immunizations (p10-11)
  - Submission of Post-mortem Autopsy Specimen (p18)
- Added ‘preschools’ to list of facilities that are required to report communicable diseases (p4)
- Clarified language in the “Submission of HIV laboratory specimens” section (p15)

# 2016 Brick Book Changes

- Added “Viral hepatitis reporting” to clarify new requirements for reporting (p16)
- Updated bibliographic information
- Updated directory of local health departments

## 8. Viral hepatitis reporting

*Note: Every new positive/reactive result should be reported, regardless of whether the patient was previously reported.*

Laboratories and physicians are required to report all positive/reactive results for hepatitis viruses to the appropriate local health department within 24 hours for the following:

### **Hepatitis A virus (HAV)**

- IgM antibodies to HAV (Anti-HAV IgM)

### **Hepatitis B virus (HBV)**

- Hepatitis B Surface Antigen (HBsAg)
- Hepatitis B e antigen (HBeAg)
- IgM antibodies to Hepatitis B Core Antigen (Anti-HBc IgM)
- HBV Nucleic Acid Tests
  - Quantitative HBV DNA (viral load)
  - Qualitative HBV DNA
  - HBV genotype
- **Report pregnancy status**, if available
- Report HBsAg and anti-HBs (POSITIVE, NEGATIVE AND INDETERMINATE) results for **children 5 years of age and younger**, by 2017 or prior if available.

### **Hepatitis C virus (HCV)**

- Hepatitis C Virus Antibody Tests (anti-HCV) – all reactive results, regardless of the signal-to-cut-off-ratio. This includes rapid or point-of-care HCV antibody tests.
- Hepatitis Nucleic Acid Tests
  - HCV Quantitative RNA results (viral load)
  - HCV Qualitative RNA results
  - HCV genotype
- **Report pregnancy status**, if available

### **Hepatitis D virus (HDV)**

- Hepatitis D surface antigen (HDsAg)
- IgM antibodies to HDV (anti-HDV IgM)

### **Hepatitis E virus (HEV)**

- IgM antibodies to HEV (Anti-HEV IgM)

# 2016 National Notifiable Diseases Changes

---

[WWW.CDC.GOV/NNDSS](http://WWW.CDC.GOV/NNDSS)



# 2016 National Changes

---

## Hepatitis C

### ➤ For Acute:

- Remove requirement for negative HAV or HBV IgM results
- Remove requirement for HCV Antibody signal to cut off ratio
- Seroconversion changed from 6 months to 12 months
- Lower ALT threshold from 400 to 200

### ➤ For Chronic:

- Remove requirement of ALTs for Probable, Chronic
- Remove requirement for HCV Antibody signal to cut off ratio

# New Conditions Under National Surveillance

---

## **Chikungunya virus neuroinvasive and non-neuroinvasive disease**

- To be added pending approval
- **Note:** the case definition for Arboviral neuroinvasive and non-neuroinvasive diseases will be revised to include Chikungunya virus to the list of nationally notifiable Arboviral diseases in the US
- Case definition link:
  - <http://wwwn.cdc.gov/nndss/conditions/chikungunya-virus-disease/>

# New Conditions Under National Surveillance

---

## **Hantavirus infection, non-Hantavirus Pulmonary Syndrome**

- To be added pending approval
- Surveillance is broadened to include both “Hantavirus Infection, Non-Hantavirus Pulmonary Syndrome and HPS so that all cases of laboratory-confirmed hantavirus infection would be nationally notifiable
- Case definition Link:
  - <http://wwwn.cdc.gov/nndss/conditions/hantavirus-infection-non-hantavirus-pulmonary-syndrome/case-definition/2015/>

# New Conditions Under National Surveillance

---

## Dengue-like illness

- To be added pending approval
- Clinical Description: Dengue-like illness is defined by fever as reported by the patient or healthcare provider
- Case Definition:
  - <http://wwwn.cdc.gov/nndss/conditions/dengue-virus-infections/case-definition/2015/>

# 2016 National Changes

---

- Change in display of Arboviral Disease data in MMWR NNDSS Table 1
  - Remove “California serogroup viruses” and replace it with “La Crosse virus” and “Jamestown Canyon virus,” the two most commonly reported California serogroup viruses.